Prime Medicine, Inc. Common Stock (PRME) is a publicly traded Healthcare sector company. As of May 21, 2026, PRME trades at $2.81 with a market cap of $507.54M and a P/E ratio of -2.08. PRME moved +0.00% today. Year to date, PRME is -20.73%; over the trailing twelve months it is +140.85%. Its 52-week range spans $1.11 to $6.94. Analyst consensus is strong buy with an average price target of $7.80. Rallies surfaces PRME's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Recent PRME insider activity includes GV 2021 GP, L.L.C. bought 1.50M, NELSEN ROBERT bought 3.03M, ARCH Venture Partners XII, LLC bought 3.03M, ARCH Venture Partners X, LLC bought 3.03M, and Liu David R. bought 21.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
| Metric | Value |
|---|---|
| Price | $2.81 |
| Market Cap | $507.54M |
| P/E Ratio | -2.08 |
| EPS | $-1.35 |
| Dividend Yield | 0.80% |
| 52-Week High | $6.94 |
| 52-Week Low | $1.11 |
| Volume | 79.85K |
| Avg Volume | 0 |
| Revenue (TTM) | $4.63M |
| Net Income | $-201.14M |
| Gross Margin | 0.00% |
8 analysts cover PRME: 0 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.80.